Clinical Trial

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase Ib trial is to find out the best dose, possible benefits and/or side effects of osimertinib and tegavivint as first-line therapy in treating patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (metastatic). Osimertinib and tegavivint may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-08-14
notable Primary completion pushed: 2026-07-31 -> 2026-12-31 2026-08-14
Trial Details
NCT Number NCT04780568
Lead Sponsor Ohio State University Comprehensive Cancer Center
Conditions Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Enrollment 24 participants
Start Date 2022-01-18
Primary Completion 2026-12-31 (estimated)
Study Completion 2029-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-13